Breakthrough lung cancer drug gets MHRA green light

News

Breakthrough lung cancer drug gets MHRA green light

In News

A cutting-edge treatment for lung cancer patients has provisionally been given the green light in the UK, meaning NHS patients will be the first in Europe to be offered it.

Sotorasib, which is taken as a tablet and is marketed as Lumykras, was granted a conditional marketing authorisation by the MHRA on Friday. It targets KRAS G12C, a mutation found in a quarter of all tumours, and has been shown to permanently lock it in an inactive state and prevent cell growth, says manufacturer Amgen UK.  

The NHS will begin offering the drug to eligible lung cancer patients within weeks through an early access agreement with Amgen, while NICE completes its appraisal process.

The announcement follows a 40-year search for a treatment for KRAS G12C. It has been approved as part of Project Orbis, an international programme between the US FDA and other regulatory agencies aimed at speeding up the review of new oncology medicines.

Described as the first drugof its kind, it is hoped that sotorasib could offer a breakthrough in the treatment of other deadly cancers including pancreatic and colorectal cancers.

Dr. Tony Patrikios, executive medical director at Amgen UK and Ireland, said: “Today’s conditional marketing authorisation by the MHRA marks an important moment in treating lung cancer patients, with a new targeted therapy, who have failed first-line treatment and face extremely poor outcomes with limited further treatment options.

“This reflects the clinical investigation programme, demonstrating the use of sotorasib in adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy.”

“Sotorasib is the first targeted KRAS G12C inhibitor to be authorised for use in Great Britain. Targeting KRAS has been a 40-year quest by scientists and researchers around the World. Approximately 13 per cent of patients with NSCLC harbour the KRAS G12C mutation and whilst approximately 48,000 people are diagnosed with lung cancer every year in the UK  it is estimated that 5,000 of these people will have KRAS G12C-mutated NSCLC.”

Professor Charles Swanton, Cancer Research UK’s chief clinician, said: “Sotorasib is one of the most exciting breakthroughs in lung cancer treatment in 20 years, targeting a cancer gene that was previously untargetable and built on decades of laboratory research that’s unravelled cancer’s inner workings.

“This medicine expands our list of effective precision therapies in lung cancer that are helping to improve survival for patients with limited options. It’s great news that patients in England will now benefit from this novel treatment.”

Record my learning outcomes

News

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share:

More like this

bookmark_icon_off
News

Scottish NES pharmacy workforce survey starts 12 September

CPS warns contractors to look out for online survey in pharmacy mailbox

1 Min Article

bookmark_icon_off
News

Pharmacy2U deliveries up 90 per cent during pandemic

P2U claims to have delivered 17 million items to patients' homes since March 2020.

1 Min Article

bookmark_icon_off
News

Government delay in agreeing Covid costs a disgrace says Meader

Numark's Jeremy Meader has criticised the government over the time taken to reach agreement on reimbursement of pharmacies' Covid costs

1 Min Article

bookmark_icon_off
News

Still no clarity on apprenticeship trailblazers

The organisation tasked with supporting a second proposal for a pharmacy apprenticeship decided not to reveal the identities of the employers

1 Min Article

bookmark_icon_off
News

NICE fails to reach agreement on new ME guidance

NICE has had to pause publication of its updated guideline on ME and CFS.

1 Min Article

bookmark_icon_off
News

RPS calls for dialogue between pharmacists & GPs

Thorrun Govind said a meeting was important for the different health professions “to understand each other’s perspectives".

1 Min Article

Recommended Learning

bookmark_icon_off
Sponsored education

Helping customers treat & care for their scalp

Understanding the causes and symptoms of some common scalp conditions will help you to make a real difference to your customers’ lives. Complete this module to discover self-care and product advice to help ease symptoms and maintain scalp health.

10 Min Module

bookmark_icon_off
Sponsored education

This module will help the pharmacy team to understand erectile dysfunction and its causes, and supply Viagra Connect to male customers affected by it, where appropriate

10 Min Module

bookmark_icon_off
Sponsored education

Sore throats and antibiotic resistance

This module will help you to understand and educate customers about the risks of antibiotic resistance, and recommend products to help them effectively manage their sore throat symptoms.

 

10 Min Module

bookmark_icon_off
Sponsored education

Supporting daily digestive health

Learn about the crucial role of gut bacteria and how a healthy microbiome can support daily digestive health

2 Min Module

bookmark_icon_off
Sponsored education

Update your knowledge of erection problems with key learning updates from recent research

2 Min Module

Sponsored education

Covid-19 and mental health

Viatris has created this short video based on a publication reviewing global research into the potential impact of the Covid-19 pandemic on mental health. It identifies six areas where psychiatrists can play a role in supporting people's mental health through these difficult times.

4 Min Module